Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 571 clinical trials
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

classes of anticancer drugs. APG-1252 is intended for the treatment of patients with neuroendocrine tumors. The purpose of the phase 1b study to establish the maximum tolerated dose (MTD), and/or

  • 0 views
  • 26 Mar, 2022
  • 1 location
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

with advanced metastatic neuroendocrine tumors. Different groups with doses of 0.37GBq-0.74GBq (10-20 mCi) and 1.85GBq (50 mCi)of 177Lu-DOTA-EB-TATE, 3.7GBq (100 mCi)of 177Lu-DOTA-TATE will be injected

radionuclide therapy
ct scan
tetraxetan
metastasis
dotatate
  • 39 views
  • 07 Oct, 2022
  • 1 location
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)

patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).

  • 0 views
  • 04 Oct, 2022
  • 1 location
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy (RADNET)

neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.

neuroendocrine carcinoma
liver metastasis
metastasis
somatostatin
neutrophil count
  • 37 views
  • 23 Feb, 2022
  • 1 location
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

This pilot phase II trial studies how effective pembrolizumab and liver-directed therapy or peptide receptor radionuclide therapy are at treating patients with well-differentiated neuroendocrine

measurable disease
radionuclide therapy
tetraxetan
metastasis
radioembolization
  • 15 views
  • 27 Feb, 2022
  • 1 location
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

patients with Grade 3 neuroendocrine tumours (NET) or neuroendocrine carcinomas (NEC).

measurable disease
lu-dota-tate
renal function
tubal ligation
hysterectomy
  • 0 views
  • 04 Oct, 2022
  • 5 locations
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in the arm). The …

  • 0 views
  • 22 Mar, 2022
  • 1 location
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a

  • 0 views
  • 07 Oct, 2022
  • 4 locations
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

This phase I trial studies the side effects of survivin long peptide vaccine and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other

  • 12 views
  • 04 Oct, 2022
  • 1 location
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Background A neuroendocrine tumor is a rare type of tumor. It comes from body cells called neuroendocrine cells. Sometimes, these tumors develop in the

  • 0 views
  • 28 Oct, 2022
  • 1 location